Upstream Bio to Present Insights on Verekitug at EAACI Congress 2025
WALTHAM, Mass. — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company focused on developing innovative treatments for inflammatory diseases, has announced a presentation at the upcoming European Academy of Allergy and Clinical Immunology Congress 2025. This event, taking place in Glasgow, UK, promises to showcase critical advancements in respiratory disorder therapies.
Highlighting TSLP Receptor Targeting
The presentation will delve into translational pharmacology modeling data that highlights the efficacy of targeting the Thymic Stromal Lymphopoietin (TSLP) receptor through verakitug. This method demonstrates a mechanism of enhanced potency compared to traditional approaches that interfere with the TSLP ligand directly.
Presentation Details
The details surrounding the presentation include:
- Title: Insights from In Silico System Pharmacology on TSLP/TSLPR Pathway Inhibition with Verekitug compared to Tezepelumab
- Presented by: Ashish Kalra, PhD, Vice President of Translational Research at Upstream Bio
- Poster Number: D3.113
- Session: TPS55 – Asthma 06
- Date and Time: June 15, 2025, from 12:45 PM to 1:45 PM BST
Deep Dive into TSLP and its Role in Inflammatory Diseases
TSLP is recognized as a crucial cytokine that triggers significant allergic and inflammatory responses, such as asthma. By disrupting TSLP signaling, researchers have identified therapeutic avenues that can significantly reduce inflammation and improve patient outcomes.
The activation of TSLP is a pivotal event that initiates a cascade of inflammatory responses, encouraging the escalation of proinflammatory cytokines such as IL-4, IL-5, and IgE. Blocking the TSLP receptor offers a unique therapeutic strategy by addressing multiple inflammatory pathways with a single intervention.
The Innovative Verekitug and Its Development
Verekitug, a recombinant fully human IgG1 monoclonal antibody, targets and inhibits the TSLP receptor, thereby preventing the initiation of proinflammatory signals. This innovative monoclonal antibody is distinct in its ability to specifically target TSLP, setting it apart from other therapies in development.
Currently, verekitug is undergoing evaluation in two major multinational Phase 2 clinical trials: the VALIANT trial for severe asthma, and the VIBRANT trial focusing on chronic rhinosinusitis with nasal polyps. Additionally, Upstream Bio is set to initiate another Phase 2 trial for chronic obstructive pulmonary disease (COPD).
Strong Preclinical and Clinical Foundation
In its preclinical assessments, verekitug exhibited remarkable binding affinity for the TSLP receptor and effectively minimized TSLP-mediated inflammation. Studies showed a significant reduction in cytokine production from immune cells, reinforcing the compound's potential across a spectrum of inflammatory-related health issues.
Completed clinical trials, including a Phase 1 single-ascending dose study and a Phase 1b multiple-ascending dose study, reveal that verekitug is well tolerated, possesses a favorable safety profile, and boasts robust pharmacokinetic characteristics.
Commitment to Patients and Future Innovations
Upstream Bio dedicates itself to addressing the unmet needs within the field of inflammatory diseases by advancing therapies like verekitug. As research and development progress, the company remains committed to leveraging the unique capabilities of verekitug to provide effective solutions for patients with chronic conditions.
For more information about Upstream Bio, please refer to their official website.
Frequently Asked Questions
What is verekitug?
Verekitug is a novel monoclonal antibody that inhibits the TSLP receptor, aiming to treat severe inflammatory diseases like asthma.
Where will the presentation take place?
The presentation will be held at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, UK.
Who is presenting the verekitug research?
Ashish Kalra, PhD, the Vice President of Translational Research at Upstream Bio, will present the findings.
What therapeutic areas does Upstream Bio focus on?
Upstream Bio focuses on developing treatments for severe respiratory disorders and other inflammatory diseases.
What are the ongoing trials for verekitug?
Ongoing trials include the VALIANT trial for severe asthma and the VIBRANT trial for chronic rhinosinusitis with nasal polyps, along with an upcoming trial for COPD.
